Published in Arch Gen Psychiatry on October 01, 1997
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 2.28
A prospective longitudinal volumetric MRI study of superior temporal gyrus gray matter and amygdala-hippocampal complex in chronic schizophrenia. Schizophr Res (2009) 1.82
Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology (2011) 1.78
Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. Schizophr Bull (2011) 1.78
Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry (2003) 1.75
Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology (2009) 1.41
Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr Bull (2008) 1.37
Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. Psychiatry Res (2012) 1.23
Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry (2013) 1.17
Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol (2015) 1.14
Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study. NMR Biomed (2009) 1.08
Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol (2008) 1.06
Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry (2005) 1.05
A framework for interpreting functional networks in schizophrenia. Front Hum Neurosci (2012) 1.05
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry (2013) 1.05
Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res (2014) 1.01
Parvalbumin neurons in the entorhinal cortex of subjects diagnosed with bipolar disorder or schizophrenia. Biol Psychiatry (2006) 0.98
Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia. Schizophr Bull (2013) 0.94
Disturbed cingulate glutamate metabolism in adults with high-functioning autism spectrum disorder: evidence in support of the excitatory/inhibitory imbalance hypothesis. Mol Psychiatry (2014) 0.93
The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93
Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia. Biol Psychiatry (2011) 0.91
Update on the neurobiology of schizophrenia: a role for extracellular microdomains. Minerva Psichiatr (2012) 0.91
Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis. Schizophr Bull (2009) 0.89
Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacology (Berl) (2013) 0.87
Two-dimensional J-resolved proton MR spectroscopy and prior knowledge fitting (ProFit) in the frontal and parietal lobes of healthy volunteers: assessment of metabolite discrimination and general reproducibility. J Magn Reson Imaging (2012) 0.86
Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis. Front Psychiatry (2013) 0.86
Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psychiatry (2014) 0.85
Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. PLoS One (2011) 0.85
Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. Schizophr Bull (2015) 0.85
Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol (2014) 0.84
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol (2011) 0.83
Imaging genetics of structural brain connectivity and neural integrity markers. Neuroimage (2009) 0.83
Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophr Res (2013) 0.83
Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 0.82
Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull (2014) 0.81
Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy. Int J Neuropsychopharmacol (2015) 0.81
Clinical and cognitive correlates of the proton magnetic resonance spectroscopy measures in chronic schizophrenia. Med Sci Monit (2012) 0.80
Phase-adjusted echo time (PATE)-averaging 1 H MRS: application for improved glutamine quantification at 2.89 T. NMR Biomed (2012) 0.79
The relation between peripheral and central glutamate and glutamine in healthy male volunteers. J Psychiatry Neurosci (2006) 0.78
Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders. Bioanalysis (2012) 0.78
T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia. Psychiatry Res (2013) 0.78
The effect of insulin infusion on the metabolites in cerebral tissues assessed with proton magnetic resonance spectroscopy in young healthy subjects with high and low insulin sensitivity. Diabetes Care (2013) 0.78
Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. Schizophr Bull (2015) 0.77
Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull (2017) 0.76
Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls. Transl Psychiatry (2015) 0.76
Theranostic Biomarkers for Schizophrenia. Int J Mol Sci (2017) 0.75
Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. Int J Mol Sci (2015) 0.75
A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. Psychol Med (2010) 2.39
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (1990) 2.13
The nature of traumatic memories: a 4-T FMRI functional connectivity analysis. Am J Psychiatry (2004) 1.95
Neural correlates of traumatic memories in posttraumatic stress disorder: a functional MRI investigation. Am J Psychiatry (2001) 1.92
A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantum. Vet Rec (1997) 1.86
BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood (1996) 1.69
An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry (1995) 1.67
Default mode network connectivity as a predictor of post-traumatic stress disorder symptom severity in acutely traumatized subjects. Acta Psychiatr Scand (2009) 1.65
Early intervention in psychosis: keeping faith with evidence-based health care. Psychol Med (2009) 1.64
An evaluation of a stress management program for individuals with schizophrenia. Schizophr Res (2002) 1.54
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A (1989) 1.47
An urban primary school health program. N Y State J Med (1991) 1.45
Comparison of the quantification precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med (2000) 1.37
The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand (2000) 1.28
Short-term modulation of glutamatergic synapses in adult rat hippocampus by NGF. Neuroreport (1994) 1.21
Aggressive treatment for postcardiac transplant lymphoproliferation. Blood (1995) 1.20
The effect of vertical and horizontal head positioning in panoramic radiography on mesiodistal tooth angulations. Angle Orthod (2001) 1.18
Factors that relate to treatment duration for patients with palatally impacted maxillary canines. Am J Orthod Dentofacial Orthop (2001) 1.18
Symptoms and cognition as predictors of community functioning: a prospective analysis. Am J Psychiatry (1999) 1.17
Quantification of myocardial blood flow and extracellular volumes using a bolus injection of Gd-DTPA: kinetic modeling in canine ischemic disease. Magn Reson Med (1992) 1.14
Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res (2000) 1.08
Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and eddy current correction. Magn Reson Med (2000) 1.07
Dual-energy mammography: initial experimental results. Med Phys (1985) 1.04
The hemicholinium-3 sensitive high affinity choline transporter is internalized by clathrin-mediated endocytosis and is present in endosomes and synaptic vesicles. J Neurochem (2003) 1.00
The response of vertebral bone mineral density during the treatment of osteoporosis with sodium fluoride. J Clin Endocrinol Metab (1989) 1.00
Ethnic diversity and pathways to care for a first episode of psychosis in Ontario. Schizophr Bull (2008) 1.00
Factors affecting the quantification of short echo in-vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed (1999) 0.99
A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol Psychiatry (1999) 0.98
A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophr Res (1996) 0.97
Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. Biochemistry (1992) 0.96
Galaxies appear simpler than expected. Nature (2008) 0.96
An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull (1996) 0.96
The use of a priori knowledge to quantify short echo in vivo 1H MR spectra. Magn Reson Med (1995) 0.96
Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci (2001) 0.96
Three syndrome concept of schizophrenia. A factor analytic study. Schizophr Res (1993) 0.95
Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease. Brain Res (1983) 0.94
Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study. Schizophr Res (1994) 0.94
EEG coherence and syndromes in schizophrenia. Br J Psychiatry (1997) 0.94
A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am J Psychiatry (1998) 0.93
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res (2002) 0.92
Human subjects exposed to a specific pulsed (200 microT) magnetic field: effects on normal standing balance. Neurosci Lett (2001) 0.91
Delusions are associated with low self-reflectiveness in first-episode psychosis. Schizophr Res (2009) 0.90
Re: The incorrect application of traditional test discriminating power formulations to diagnostic-group studies. J Nerv Ment Dis (1984) 0.90
Biofeedback therapy for headache and other pain: an evaluative review. Pain (1979) 0.90
Toward a model of cognitive insight in first-episode psychosis: verbal memory and hippocampal structure. Schizophr Bull (2009) 0.90
Neuropsychological correlates of syndromes in schizophrenia. Br J Psychiatry (1997) 0.89
The interaction between hexamethonium and tubocurarine on the rat neuromuscular junction. Br J Pharmacol (1984) 0.89
Relationship of obsessive-compulsive symptomatology to anxiety, depression and schizotypy in a clinical population. Br J Clin Psychol (1996) 0.89
Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites. J Med Chem (1998) 0.88
Nuclear localization of the 82-kDa form of human choline acetyltransferase. J Biol Chem (1999) 0.88
Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother (1995) 0.87
Declining of memory functions of normal elderly persons. Psychiatry Clin Neurosci (2000) 0.87
Quantifying 1H decoupled in vivo 31P brain spectra. NMR Biomed (1999) 0.86
Time-varying magnetic fields increase cytosolic free Ca2+ in HL-60 cells. Am J Physiol (1990) 0.86
Comparison between tungsten and steel polypectomy snares: evaluation of depth of colonic thermal wall injury in a pig model. Endoscopy (2013) 0.86
Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K. Bioorg Med Chem (1999) 0.86
Preparation for undergoing an invasive medical procedure: interacting effects of information and coping style. J Consult Clin Psychol (1993) 0.85
EEG abnormalities and 3-year outcome in first episode psychosis. Acta Psychiatr Scand (2007) 0.85
Life events and relapse in schizophrenia. A one year prospective study. Soc Psychiatry Psychiatr Epidemiol (1990) 0.85
Electroencephalography as an aid in the exclusion of Alzheimer's disease. Arch Neurol (1994) 0.84
Assessing health utilities in schizophrenia. A feasibility study. Pharmacoeconomics (2000) 0.84
Coherence on electroencephalography and aberrant functional organisation of the brain in schizophrenic patients during activation tasks. Br J Psychiatry (1991) 0.84
A dynamic vulnerability perspective on stress and schizophrenia. Am J Orthopsychiatry (1992) 0.84
Frontal and non-frontal lobe neuropsychological test performance and clinical symptomatology in schizophrenia. Psychol Med (1992) 0.84
A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol Psychiatry (1999) 0.83
Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism. Psychopharmacology (Berl) (1994) 0.83
Relationship between neurological 'soft signs' and syndromes of schizophrenia. Acta Psychiatr Scand (1997) 0.83
Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors. Psychopharmacology (Berl) (1992) 0.83
Heart beat interoception: a study of individual differences. Int J Psychophysiol (1985) 0.83
An investigation into movement planning and execution deficits in individuals with schizophrenia. Schizophr Res (1997) 0.82